🚀 VC round data is live in beta, check it out!
Spermosens Valuation Multiples
Discover revenue and EBITDA valuation multiples for Spermosens and similar public comparables like Elite Diagnostic, Level Bio, Lumito, Genetic Analysis and more.
Spermosens Overview
About Spermosens
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.
Founded
2018
HQ
Employees
4
Website
Financials (FY)
EV
$3M
Spermosens Financials
Spermosens reported last fiscal year revenue of — and negative EBITDA of ($985K).
In the same fiscal year, Spermosens generated ($985K) in EBITDA losses and had net loss of ($1M).
Spermosens P&L
In the most recent fiscal year, Spermosens reported revenue of — and EBITDA of ($985K).
Spermosens expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($985K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Spermosens Stock Performance
Spermosens has current market cap of $3M, and enterprise value of $3M.
Market Cap Evolution
Spermosens' stock price is $0.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3M | $3M | 0.3% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSpermosens Valuation Multiples
Spermosens trades at (2.6x) EV/EBITDA.
Spermosens Financial Valuation Multiples
As of April 20, 2026, Spermosens has market cap of $3M and EV of $3M.
Equity research analysts estimate Spermosens' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Spermosens has a P/E ratio of (3.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (2.6x) | XXX | XXX | XXX |
| P/E | — | XXX | (3.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Spermosens Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Spermosens Margins & Growth Rates
Spermosens' revenue in the last fiscal year grew by —.
Spermosens' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Spermosens Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 0% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Spermosens Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Spermosens | XXX | XXX | XXX | XXX | XXX | XXX |
| Elite Diagnostic | XXX | XXX | XXX | XXX | XXX | XXX |
| Level Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Lumito | XXX | XXX | XXX | XXX | XXX | XXX |
| Genetic Analysis | XXX | XXX | XXX | XXX | XXX | XXX |
| Attana | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spermosens M&A Activity
Spermosens acquired XXX companies to date.
Last acquisition by Spermosens was on XXXXXXXX, XXXXX. Spermosens acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Spermosens
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSpermosens Investment Activity
Spermosens invested in XXX companies to date.
Spermosens made its latest investment on XXXXXXXX, XXXXX. Spermosens invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Spermosens
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Spermosens
| When was Spermosens founded? | Spermosens was founded in 2018. |
| Where is Spermosens headquartered? | Spermosens is headquartered in Sweden. |
| How many employees does Spermosens have? | As of today, Spermosens has over 4 employees. |
| Is Spermosens publicly listed? | Yes, Spermosens is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Spermosens? | Spermosens trades under SPERM ticker. |
| When did Spermosens go public? | Spermosens went public in 2021. |
| Who are competitors of Spermosens? | Spermosens main competitors are Elite Diagnostic, Level Bio, Lumito, Genetic Analysis. |
| What is the current market cap of Spermosens? | Spermosens' current market cap is $3M. |
| Is Spermosens profitable? | No, Spermosens is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.